Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll EphA2 overexpression is associated with angiogenesis in ovarian cancer Lin YG; Han LY; Kamat AA; Merritt WM; Landen CN; Deavers MT; Fletcher MS; Urbauer DL; Kinch MS; Sood AKCancer 2007[Jan]; 109 (2): 332-40BACKGROUND: EphA2 is overexpressed in the majority of ovarian cancers and predicts poor clinical outcome. Based on EphA2's emerging role in angiogenesis, we hypothesized that tumors overexpressing EphA2 demonstrate greater microvessel density (MVD) and matrix metalloproteinase (MMP) expression. METHODS: After Institutional Review Board (IRB) approval, 77 invasive epithelial ovarian tumors were analyzed for CD31, EphA2, MMP-2, MMP-9, and MT1-MMP expression. RESULTS: The median age of the patients was 59 years (range, 34-83). EphA2 was overexpressed in 76% of tumors and was associated with advanced-stage disease (P < .001) and high-grade histology (P = .04). MVD was stratified into high (>12.7 vessels/high-power field [HPF]) versus low (|Adult[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|Female[MESH]|Humans[MESH]|Immunohistochemistry[MESH]|Kaplan-Meier Estimate[MESH]|Matrix Metalloproteinase 14/analysis[MESH]|Matrix Metalloproteinase 2/analysis[MESH]|Matrix Metalloproteinase 9/analysis[MESH]|Middle Aged[MESH]|Neovascularization, Pathologic/metabolism/*pathology[MESH]|Ovarian Neoplasms/blood supply/metabolism/*pathology[MESH]|Platelet Endothelial Cell Adhesion Molecule-1/analysis[MESH]|Receptor, EphA2/*analysis[MESH] |